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BACKGROUND AND PURPOSE: Accurate assessment of the number and lesion characteristics of brain
metastasis is very important in GKS. The purpose of this study was to compare the diagnostic efficacy
of DD gadobutrol in the detection of brain metastases compared with a DD 0.5-mol/L gadolinium
contrast, gadopentetate dimeglumine.
MATERIALS AND METHODS: Records of 27 patients (male to female ratio, 15:12; mean age, 57.1 years)
diagnosed with brain metastasis and having undergone GKS were retrospectively analyzed. All patients
underwent the first 3D-T1-GRE MR imaging with a DD of gadopentetate dimeglumine. The second MR
imaging with a DD of gadobutrol was performed during GKS by using the same parameters used for the
first scan. Two neuroradiologists counted the number of enhancing lesions on 2 consecutive MR imaging
examinations and reached consensus. Lesion-brain CNR was measured from 45 lesions, and paired t test
analysis was performed between DD gadopentetate dimeglumine and gadobutrol MR imaging.
RESULTS: On DD gadopentetate dimeglumineenhanced images, a total of 130 lesions were de-
tected visually. With DD gadobutrol, 25 additional lesions were detected on GKS MR imaging. There
was no missing lesion on DD gadobutrol MR imaging. The mean lesion-brain CNR was higher on DD
gadobutrol MR imaging than on DD gadopentetate dimeglumine imaging (2.17  0.19 versus 1.90 
0.26; P  .00011, paired t test, 2-tailed). Only 2 cases showed lower CNR on DD gadobutrol images:
1 with hemorrhagic metastasis from renal cell carcinoma and the other with steroid treatment after the
first MR imaging.
CONCLUSIONS: DD 1.0-mol/L gadobutrol provides higher lesion conspicuity and enhances lesion
detection in brain metastasis compared with DD 0.5-mol/L gadolinium contrast agents.
ABBREVIATIONS: CNR  contrast-to-noise ratio; DD  double dose; Gd  gadolinium; GKS 
gamma knife surgery; GRE  gradient recalled-echo
For therapeutic planning, it is critical to obtain the exactnumber and location of brain metastases. Only then can
patients take advantage of recent advances in targeted radio-
surgery, which has produced promising results such as higher
survival rates.1,2 Compared with CT or unenhanced MR im-
aging, the diagnostic yield of contrast-enhanced brainMR im-
aging in the detection of brain metastasis is very high.3-5
Adjusting various parameters duringMR imaging has been
considered very important in achieving higher sensitivity in
the detection of enhancing lesions or vascular structures.
Among these, modification of the administered Gd dose is
thought to raise the diagnostic efficacy in brain lesions.4,6-12
Among the recently available MR imaging contrast media,
gadobutrol (gadolinium-DO3A-butriol, Gadovist 1.0; Scher-
ing, Berlin, Germany) is the first commercially available 1.0-
mol/L gadolinium chelate, a macrocyclic chelate not a linear
one.12-17 The lower osmolality and viscosity of gadobutrol en-
ables the double-concentrated solution, which contains twice
the amount of Gd chelate per volume.12-17 The T1 relaxivity of
gadobutrol is approximately 14%–27% higher than that of
other 0.5-mol/L Gd chelates.18
Higher dose administration is known to be more effective
in lesion detection, but consideration must be given to reduc-
ing the amount of gadolinium administered to the patient
because of the risk of contrast-related reactions and nephro-
genic systemic fibrosis.19,20 Gadobutrol had been proved to be
a safe MR imaging contrast agent in patients with impaired
renal function at doses of0.3mmol/L/kg of weight,18 and no
nephrogenic systemic fibrosis has been reported so far.17
At this point,we canpostulate thatDDgadobutrol is expected
to offer better opportunity for further improved enhancement
thanotherGd contrast agents because of the higherT1 relaxation
effect. However, there have been few documented data of the
clinical benefits in the detection of brain disease in contrast to
other 0.5-mol/L Gd contrast agents.17 The purpose of this study
was to compare the diagnostic efficacy ofDD1.0-mol/L gadobu-
trol in the detection of brain metastasis compared with DD 0.5-
mol/L gadopentetate dimeglumine.
Materials and Methods
Patient Population
Retrospective analysis was performed for patients who were diag-
nosed with brainmetastasis and had undergone GKS fromDecember
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2008 toMarch 2009. In total, 27 patients (male to female ratio, 15:12;
mean age, 57.1 years; range, 14–77 years) were involved, and their
primary sites were the lung (n  22), kidney (n  2), liver (n  1),
colon (n 1), and rectum (n 1). The study protocol was approved
by the institutional review board.
MR Imaging and Contrast Agent Administration
At the outpatient oncology clinic, patients who had neurologic symp-
toms routinely underwent MR imaging for metastasis protocol after
being injected with DD gadopentetate dimeglumine. If the patient
was found to have brain metastasis and if indicated for GKS, the
patient was referred to the neurosurgery department and underwent
localization MR imaging for GKS after being injected with DD
gadobutrol.
All examinations were performed with a 1.5T scanner (Achieva or
Intera; Philips Medical Systems, Best, the Netherlands). Each patient
was scanned twice with the same 3D-T1-GRE imaging after receiving
an injection of DD Gd contrast agent (ie, 0.2 mmol/L/kg). The injec-
tion contained 0.2 mL/kg of gadobutrol and 0.4 mL/kg of gado-
pentetate dimeglumine because gadobutrol is a 1.0-mol/L agent and
its concentration is twice as high as that of gadolinium. Amechanical
injector was used with the rate of 2 mL/s followed by a 20-mL normal
saline infusion.
An institutional MR imaging protocol for brain metastasis in-
cluded routine anatomic T1/T2-weighted and GKS imaging as well as
a T1-weighted 3D-GRE sequence after injection of 0.2-mmol/L/kg
Gd contrast agents. Axial image reconstruction was made parallel to
the anterior/posterior commissure line. The parameters of T1-
weighted 3D-GRE imaging were as follows: TR/TE, 26/4.5 ms; flip
angle, 8°; bandwidth, 190.8 Hz/pixel; 256 256 matrix with 160- to
180-second axis phase-encoding steps; 1-mm section thickness; and a
25-cm FOV. Scanning time was 7 minutes 41 seconds. Post-Gd im-
aging was started at 4 minutes after injection of Gd contrast. The
interval between 2 consecutive scannings ranged from 2 to 11 days
(mean, 4.3 days).
Imaging Analysis
Two board-certified neuroradiologists (E.S.K., S.-K.L.) with 6
years’ experience in brain MR imaging interpretation reviewed the
enhanced MR images. They were fully blinded to the contrast agent
used in each examination for all patients. Each blinded reader evalu-
ated the patients’ images separately and independently. They counted
the number of enhancing lesions with agreement and directly com-
pared DD gadopentetate dimeglumine and gadobutrol-enhanced
MR images.
The lesion-to-brain CNR was evaluated by using region-of-inter-
est measurements. Regions of interest were placed within the enhanc-
ing portion of the metastatic lesions and in the contralateral normal
white matter, excluding the ventricular system, to avoid partial vol-
ume effects. Care was taken to place the region of interest in an area of
homogeneous contrast enhancement within the metastasis. Regions
of interest were limited to the largest 3 lesions in the cases in which
there were3metastatic lesions. A total of 45 lesions weremeasured,
and the lesion-brain CNR was calculated. A paired t test was used for
comparison of DD gadopentetate dimeglumine and gadobutrol-
enhanced MR imaging.
Results
On the DD gadopentetate dimeglumineenhanced images, a
total of 130 lesions were detected. Among 27 patients, 13 pa-
tients had a solitary lesion, 3 had 2 lesions, another 2 had 3
lesions, and 9 had multiple lesions. With DD gadobutrol, 25
additional lesions were detected on localization MR imaging
for GKS in 7 patients (Fig 1). All 25 lesions were not evident on
DD gadopentetate dimeglumine images. Of the 25 lesions, 1
patient had a solitary lesion, 3 had 2 lesions, 2 had 3 lesions,
and 1 had 12 lesions.
The lesion-brain CNR was higher on DD gadobutrol MR
imaging (2.17 0.19 versus 1.90 0.26; P .00011, paired t
test, 2-tailed) (Fig 1). Gadobutrol MR images showed thicker
enhancing rims of metastatic masses (Fig 2) and better lesion
contrast than gadopentetate dimeglumine images (Fig 3).
Only 2 cases had lower CNR on DD gadobutrol images: 1 had
hemorrhagic metastasis from renal cell carcinoma and an-
other started steroid treatment after the firstMR imaging. The
CNR was 1.78 on gadobutrol MR imaging and 2.25 on gado-
pentetate dimeglumineMR imaging in the first patient. In the
Fig 1. Comparison of lesion CNR between gadopentetate dimeglumine and gadobutrol. The
mean CNR of enhancing lesions is significantly higher with gadobutrol.
Fig 2. A 63-year-old woman with lung cancer. Gadobutrol MR imaging shows more
enhancing lesions than gadopentetate dimeglumine MR imaging (arrow in the right
precentral gyrus). Retrospective review of gadopentetate dimeglumine images suggests the
existence of a small nodule in the right precentral gyrus, but it is not definite. A thicker
enhancing rim and prominent gadolinium spillage are seen on gadobutrol MR imaging
(arrowheads).
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second patient, the CNR was 2.29 on gadobutrol MR imaging
and 2.73 on gadopentetate dimeglumine MR imaging.
Discussion
In this study, we retrospectively analyzed the results of DD
gadopentetate dimeglumine and gadobutrol in the detection
of brain metastasis. Patients who showed neurologic symp-
toms or were suspected of having brain metastasis were ad-
ministered DD gadopentetate dimeglumine in the outpatient
clinic. The subjects were transferred to the neurosurgery de-
partment if they were confirmed to have hematogenous brain
metastasis on MR imaging and, thus, were potential candi-
dates for GKS. There, they received a second MR imaging for
localization of metastatic lesions after setting of the gamma
knife frame. It is extremely difficult for cancer patients to un-
dergo simultaneous scanning with 2 different contrast agents.
To avoid that, we decided to conduct a retrospective analysis
of GKS patients as an alternative way to assess the efficacy of
gadobutrol in the detection of brain metastasis.
Gadobutrol is a hydrophilic neutral macrocyclicMR imag-
ing contrast agent with predominantly extracellular distribu-
tion in humans.16,18,21 Gadobutrol had been proved to be a
safe MR imaging contrast agent in patients with impaired re-
nal function at doses of0.3 mmol/L/kg of body weight.22 So
far, there have been no reports of nephrogenic systemic fibro-
sis in association with the administration of gadobutrol.23 The
T1 relaxivity of gadobutrol is approximately 14%–27% higher
than that of other Gd chelates, with lower molarity, except
0.5-mol/L gadobenate dimeglumine (MultiHance; Bracco,
Milan, Italy), which also has a high T1 relaxivity.18 In animal
models of glioma, gadolinium concentration in the mass after
gadobutrol injection is higher than that with other gadolinium
chelates.24 On the basis of these previous studies, we can as-
sume that the CNR of enhancing lesions after gadobutrol ad-
ministration ismuch higher than that of other Gd compounds
in the clinical field, but no documented data have been re-
ported yet, to our knowledge.
Determination of the number and accurate localization of
metastatic lesions is critical in GKS compared with other mo-
dalities such as chemotherapy, whole brain radiation therapy,
or surgery.25 Therefore, selection of excellent contrastmedia is
very important in diagnosing brainmetastasis and in the treat-
ment plan. Because gadobutrol has been approved for clinical
use by the Korean Food and Drug Administration and was
commercialized the following year, neurosurgeons in our in-
stitution prefer gadobutrol for localization MR imaging be-
cause of the safety profile and higher CNR of gadobutrol;
therefore, most of our localization MR imaging was per-
formed after administration of gadobutrol.
Previous reports described the superiority of gadobutrol in
contrast-enhanced MR angiography, perfusion MR imaging,
and demyelinating disease.26-28 These articles reported in-
creased diagnostic accuracy and the stable chemical and phar-
macologic properties of gadobutrol, which are safer than those
of previously used agents. For gadobutrol, only half the
amount of the previously used 0.5-mol/LGd contrast agents at
the same concentration is enough. Thus, it is more suitable for
rapid bolus injection for MR angiography and perfusion MR
imaging.
A recent intraindividual comparison study by Anzalone et
al20 showed the superior power of gadobutrol in the detection
of brain metastasis. They analyzed 2-mm-thick 3D GRE im-
ages and determined lesion conspicuity by visual analysis. We
have a similar study design, but we have more qualitative data
with measurement of lesion CNR and higher resolution im-
ages with 1-mm thickness. In routine clinical practice, DD
administration with thin-section GRE imaging is common for
the evaluation of metastasis. Therefore, our results have addi-
tional significance in the diagnostic accuracy of contrast-
enhanced MR imaging in the oncology clinic.
There are some limitations to this study. First, prospective
study design and simultaneous scanning with 2 different Gd
contrast agents were nearly impossible for cancer patients, and
we chose a retrospective analysis. Therefore, the time interval
between the 2 MR imaging scans varied from 2 to 11 days
(mean, 4.3 days). However, many enhancing lesions with 2- to
3-day intervals showedmore apparent differences than lesions
with longer intervals. Therefore, we postulated that these re-
sults are enough to show the higher capacity of gadobutrol in
the detection of brain metastasis.
The use of a steroid is another problem. In the cases of
brain edema and increased intracranial pressure, dexametha-
sone is usually administered, and it decreases the membrane
permeability and the degree of contrast enhancement.29 Seven
of 27 patients received steroid therapy during the interval
between the 2 MR imaging scans. Only 1 showed decreased
lesion-brain CNR, and the others showed higher CNR with
gadobutrol MR imaging. With some limitations of a retro-
spective study design, these results show the definite superior-
ity of gadobutrol in diagnostic accuracy and in the detection of
brain metastasis.
Conclusions
DD gadobutrol is much more effective in detecting brain me-
tastases and provides higher lesion conspicuity in enhancing
metastasis; more clinical application is expected.
Fig 3. A 60-year-old man with lung cancer. Gadobutrol MR imaging shows more enhancing
lesions than gadopentetate dimeglumine MR imaging (arrows). There is no suspected
lesion on gadopentetate dimegluimine MR imaging. Note the higher signal intensity of the
thick enhancing rim (arrowheads). The interval between the 2 MR images is 60 hours.
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